Interspecies extrapolation by physiologically based pharmacokinetic modeling

نویسنده

  • Ahmed Ghallab
چکیده

Recently, Christoph Thiel and colleagues from Aachen University published an improved physiologically based pharmacoki-netik modeling (PBPK) technique for mouse to human extrapolation (Thiel et al., 2015). This publication will be awarded by the Ebert Prize 2016 of the American Pharmacist Association, which represents the oldest pharmacy award in the United States. The translation of preclinical knowledge often generated in mice to first-inhuman studies represents a critical step (Thiel et al., 2015). More than 30 % of developmental compounds fail due to interspecies differences. To improve the situation, the authors used PBPK modeling to predict human plasma concentration-time profiles based on mouse data. The study was based on 10 exemplary drugs for which a comprehensive pharmacokinetic database is available. Mouse to human extrapolation was achieved by adjustment of four model parameter domains (Thiel et al., 2015): (1) species-specific physiology, such as differences in organ size, perfusion, etc. (2) the species-specific non-protein bound fraction of the test compound, (3) kinetic parameters, such as V max and K M for the primary route of excretion, and (4) tissue-specific gene expression of the metabolizing key enzymes and transporters. The authors start with a naïve extrapola-tion where humans are considered as 'large mice' where the same dose per body weight was administered (Thiel et al., 2015). This naïve extrapolation usually resulted in predictions that strongly deviate from the real human situation. Next the authors showed that knowledge-based adjustment of each of the four model domains leads to an improvement and allows predictions which closely resemble the measured situation in humans. A limitation of the current approach is that gene expression data were used to adjust for interspecies differences in metabolism. In future, predictions may become even more accurate if RNA based data could be replaced by metabolic activities. Interspecies differences represent a major problem in toxicology (Dohnal et al. Rodent to human comparisons have often been performed by comparing data in human and mouse or rat hepatocytes (Carmo et al. differences in metabolism represent only one of several aspects which can explain inter-species differences.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Proposed Approach to Efficiently Develop Physiologically Based Pharmacokinetic (PBPK) & Physiologically Based Pharmacokinetic-Pharmacodynamic (PBPK-PD) Models for Pesticides

The standard approach to extrapolating from animals to humans (inter-species) or across the human population (intra-species) in risk assessment is to apply 10X uncertainty factors. In Science and Decisions: Advancing Risk Assessment (NRC, 2009), the NAS recommends that the agency “...continue and expand use of the best, most current science to support and revise default assumptions.” EPA publis...

متن کامل

Prediction of Deoxypodophyllotoxin Disposition in Mouse, Rat, Monkey, and Dog by Physiologically Based Pharmacokinetic Model and the Extrapolation to Human

Deoxypodophyllotoxin (DPT) is a potential anti-tumor candidate prior to its clinical phase. The aim of the study was to develop a physiologically based pharmacokinetic (PBPK) model consisting of 13 tissue compartments to predict DPT disposition in mouse, rat, monkey, and dog based on in vitro and in silico inputs. Since large interspecies difference was found in unbound fraction of DPT in plasm...

متن کامل

Pharmacokinetics, Pharmacodynamics and Drug Metabolism Interspecies Scaling in Pharmacokinetics: A Novel Whole-Body Physiologically Based Modeling Framework to Discover Drug Biodistribution Mechanisms In Vivo

Drug approval processes require extensive testing and have recently put more emphasis on understanding mechanistic drug action in the body including toxicity and safety.1 Consequently, there is an urgent need in the pharmaceutical industry to develop mechanistic pharmacokinetic (PK) models able to both expedite knowledge gain from experimental trials and, simultaneously, address safety concerns...

متن کامل

Physiologically based pharmacokinetics and cancer risk assessment.

Physiologically based pharmacokinetic (PBPK) modeling involves mathematically describing the complex interplay of the critical physicochemical and biological determinants involved in the disposition of chemicals. In this approach, the body is divided into a number of biologically relevant tissue compartments, arranged in an anatomically accurate manner, and defined with appropriate physiologica...

متن کامل

Charge the SAP for the October 24-27 2017 Meeting on Physiologically Based Pharmacokinetic Modeling to Address Pharmacokinetic Differences Between and Within Species

The 2009 National Research Council report “Science and Decisions”1 recommends that the agency uses the best, most current science, to support or revise the default assumptions in the agency’s risk assessments. In addition, the 2013 Institute of Medicine report on “Environmental Decisions in the Face of Uncertainty”2 further recommends replacing default uncertainty factors with data-derived extr...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 14  شماره 

صفحات  -

تاریخ انتشار 2015